A message from our CEO

I’m very proud of the progress our company continues to make in advancing sustainability reporting. We see an inherent connection between sustainability and strategy and are excited to share our latest progress with our stakeholders. Through these efforts and the work of our incredible employees, we will advance our mission and make a positive, lasting impact on the world.

Our Sustainability Journey

Listen

The pursuit of continuous improvement drives our global efforts at Dexcom. We pay attention to the evolving needs of our customers, healthcare providers, employees, researchers, payors, and other key stakeholders to exemplify the first of our four core values: Listen. We believe listening to our stakeholders is critical to the ongoing success of our business.

Listen

Be dependable

Dexcom seeks to exemplify quality in all aspects of the organization. While our end goal is the production of the highest-caliber CGM devices that empower people to take control of health, achieving this goal requires an even broader approach. Our culture of quality requires us to foster an environment where every Dexcom employee understands their essential role in designing, testing, and manufacturing our devices that are used every day by our customers. We emphasize this commitment in the core value: be dependable.

Be dependable

Serve with integrity

Dexcom is committed to operating with the highest standards of ethics, as captured in the core value: serve with integrity. This commitment extends to all aspects of the organization including:

  • The safety and effectiveness of our products
  • The way we serve and empower our customers and employees
  • Our focus on innovation as we seek to address issues of customer access to our product
  • The way we communicate our story to our stakeholders

Governance Documents

Executive Management

Board of Directors

Committee Composition

Key Stats

2.8M+

At year-end 2024, Dexcom served greater than 2.8 million customers globally.

Billions

Dexcom G6, Dexcom G7, and Dexcom ONE have enabled people with diabetes to forego billions of fingersticks.

$5,000+
/year

Real-time CGM has demonstrated annual cost savings of greater than $5,000 among customers with type 2 diabetes.1

1. https://www.hcplive.com/view/real-time-cgm-use-associated-with-reduced-medical-costs-in-patients-with-type-2-diabetes